Gold-standard clinical trials fail to capture how behavior changes influence treatment

Double-blind clinical trials for new drugs are considered the 'gold standard' of medical research but one effect these trials fail to measure is how a medication's performance can vary based on patients' lifestyle choices, according to a new study. Researchers propose a new trial design that can measure such interactions between behavior and treatment.